~ In PATH-1 and PATH-2 upacicalcet met primary and key secondary endpoints of reducing parathyroid hormone (PTH) in patients with end-stage kidney disease and Secondary Hyperparathyroidism (SHPT) on hemodialysis ~ Upacicalcet also reduced FGF23 and markers of bone turnover in the trial...
Hence then, the article about pathalys pharma presents positive data from pivotal phase 3 studies of upacicalcet in featured oral presentation at asn kidney week 2026 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Pathalys Pharma Presents Positive Data from Pivotal Phase 3 Studies of Upacicalcet in Featured Oral Presentation at ASN Kidney Week 2026 )
Also on site :
- Axon Announces Body 5: Next-Generation Camera Built for the AI Era
- Cynthia Erivo Plays Glinda in ‘Nigerian Wicked’ Sketch on ‘SNL U.K.’: ‘She Wants a BBL That Defies Gravity’
- Former Child Star Larry Mathews Struggled to Find Acting Jobs After ‘The Dick Van Dyke Show’ Ended; Here’s What He Did Instead